Chapter 4: Genetic Control of Cell Function and Inheritance

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement, not replace, the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we're tackling something really foundational.

We're diving deep into the blueprint of life itself, genetic control and inheritance.

That's right.

We're using Porth's chapter on this as our guide.

And honestly, this stuff underpins everything in pathophysiology.

It really does.

I mean, think about it.

Cell function, what you look like, your risk for certain diseases, even how you respond to drugs.

It all comes back to this genetic blueprint.

Absolutely.

So our mission, if you will, is to break down this complexity.

We're going from the DNA double helix all the way up to modern gene tech.

We want you to have those aha moments along the way.

We'll cover structure, function, how traits get passed down, and even some of the cutting edge applications.

Okay, so we're looking at this really comprehensive summary of genetic control in humans.

Let's jump right in with the molecules that actually hold the code.

Alright, so DNA.

Everyone pictures that double helix, right?

It's incredibly stable.

Super stable.

And if you zoom right in, you see it's made of nucleotides.

Each one has a phosphate, a deoxyribose sugar.

And what a four -nitrogenous basis.

Adenine, thymine, cytosine, guanine, ATC, G.

And the really critical part here is how they pair up.

A always goes with T, and G always pairs with C, held together by hydrogen bonds.

It's like a perfect chemical lock and key.

Exactly.

And that precise pairing, that complementarity, is what makes DNA so good at its job.

It means it can be copied almost perfectly, and if there's damage, the cell knows how to repair it using the other strand as a template.

Which brings us to replication.

Porth describes this semi -conservative model.

Can you walk us through that, like, visually?

Yeah, sure.

Imagine that DNA helix is like a zipper.

For replication, you unzip it, separating the two original strands.

Why?

Then each of those original strands acts as a template.

The cell builds a brand new complementary strand alongside each old one, a pair with T, G pairs with C, all the way down.

So you end up with two DNA molecules.

Two identical DNA molecules, and here's the semi -conservative bit.

Each new molecule has one old strand from the original parent DNA, and one newly made strand.

Ah, I see.

So you're conserving half of the original in each copy.

Clever.

It's a fantastic system for fidelity.

It keeps the information stable across generations of cells.

Okay, so that's DNA, the master library, super stable.

But then there's RNA, it's more like the working copy, right?

What's different about it?

Several key things.

RNA usually uses ribose sugar instead of deoxyribose.

It's typically single -stranded, not double.

And chemically, it swaps out thymine T for a different base called uracil, U.

So an RNA, A, pairs with U.

And being single -stranded and slightly less stable makes it better for its job.

Yeah, you could say that.

It's designed to be temporary.

It's made when needed to carry the instructions for building a protein, does its job, and then it gets broken down.

It's the messenger molecule.

Got it.

Now, before we get into how proteins are made, let's define a couple of terms.

We hear genome a lot.

That's the entire DNA blueprint.

But what's the proteome?

Good question.

If the genome is the complete set of instructions, the proteome is the complete set of proteins that can be made from those instructions in a cell or organism.

So all the actual workers and machines in the cell.

Exactly.

And proteomics is just the study of that whole protein set.

What proteins are how many, how they interact.

It's hugely important because proteins do almost everything.

Understanding the proteome is key to understanding disease.

OK, so we have the DNA blueprint in the nucleus.

How does the cell actually read a specific gene and start making a protein?

That first step is called transcription, basically copying the DNA sequence of a gene into a complementary strand of messenger RNA or mRNA.

And this happens inside the nucleus.

Right where the DNA is stored.

The main enzyme doing the copying is RNA polymerase.

Does it just start copying anywhere?

No, no.

It's tightly controlled.

RNA polymerase needs to bind to a specific start here signal on the DNA called the promoter region.

You often hear about the TATA box, which is part of many promoters.

And it needs help to bind there.

Often, yes.

Special proteins called transcription factors are involved.

Some help the polymerase bind and get started.

That's called induction, increasing gene expression.

Others can block it.

That's repression, decreasing expression.

It's like the cell's dimmer switch for each gene.

OK, so the RNA polymerase makes an initial RNA copy.

Is that copy ready to go straight away?

Not quite.

In eukaryotes like us, that initial RNA transcript needs some processing.

Think of it like editing a rough draft.

What kind of editing?

A couple of things.

Protective caps and tails are added to the ends of the RNA molecule.

And then there's splicing.

Ah, splicing.

This is where the introns and exons come in, right?

Exactly.

The initial RNA copy contains sections that actually code for the protein.

Those are the exons and sections that don't, which are called introns.

Splicing cuts out the introns and joins the exons together to make the final mature mRNA.

Why have introns at all if they just get cut out?

Seems inefficient.

It seems that way, but it's actually incredibly powerful.

It allows for alternative splicing.

The cell can splice the exons together in different combinations.

Meaning one gene.

Can actually produce multiple different versions of a protein.

Korth mentions tropomyosin.

One gene can make 10 different versions of that protein in muscle cells, just through alternative splicing.

It massively increases the coding potential of the genome.

Wow, okay.

So the mature mRNA with introns removed and exons spliced is ready.

What happens next?

It travels out of the nucleus into the cytoplasm.

That's where the protein building machinery, the ribosomes are located.

And this next step is translation.

Correct.

Translation is decoding the mRNA sequence to build a chain of amino acids, a polypeptide, which will become the protein.

The ribosome essentially reads the mRNA sequence.

How does it read it?

It reads it in three base chunks called codons.

Each codon specifies a particular amino acid.

Okay, so AUG means start and also methionine, for example.

But how do the amino acids actually get brought to the ribosome?

That's the job of another type of RNA.

Transfer RNA or tRNA.

Think of tRNA molecules as adapters or delivery trucks.

Yeah.

One end of a tRNA molecule recognizes a specific mRNA codon, and the other end carries the corresponding amino acid.

So the tRNA reads the mRNA codon on the ribosome and delivers the correct amino acid to be added to the growing chain.

Makes sense.

And you mentioned the code is redundant.

Right, or degenerate.

There are 64 possible codons, four bases taken three at a time, but only 20 standard amino acids.

So most amino acids are specified by more than one codon, like AAA and AG, both code for lysine.

Does that redundancy help?

It does.

It provides a buffer against mutations.

A small change in the DNA might change the codon, but if it changes it to another codon for the same amino acid, the protein sequence isn't affected.

It adds robustness to the system.

So the ribosome chugs along the mRNA, tRNA brings the amino acids, and you get this long polypeptide chain.

Is the protein finished then?

Almost, but not quite.

That polypeptide chain is just a linear sequence.

To be functional, it has to fold up into a very specific, complex three -dimensional shape.

And that folding happens automatically?

Sometimes, but often it needs help.

Special proteins called molecular chaperones assist in the folding process.

They prevent misfolding or aggregation.

And if that goes wrong,

that's where pathology can come in.

Absolutely.

Porth highlights this.

If chaperones fail or proteins are prone to misfolding, they can clump together, forming insoluble aggregates or inclusion bodies.

This is exactly what happens in diseases like Parkinson's, Alzheimer's, and Huntington's.

Misfolded proteins accumulating and causing damage.

So that final folding step aided by chaperones is absolutely critical for function.

Okay, let's talk about organization.

You mentioned the human genome is huge, like two meters of DNA per cell.

How on earth does that fit inside a tiny nucleus?

Yeah, it's an amazing packaging feat.

The DNA isn't just crammed in there randomly.

It's wrapped around proteins called histones.

Like beads on a string.

Sort of, yeah.

That DNA histone complex is called chromatin.

This coiling and folding packs the DNA very tightly.

Does that packaging affect whether genes can be read?

Definitely.

It's not just about saving space, it's also about access control.

Tightly packed chromatin, called heterochromatin, generally means the genes in that region are switched off, inaccessible.

Looser packed chromatin, euchromatin, allows the machinery access to transcribe the genes.

Can the cell change how tightly packed it is?

Yes, that's chromatin remodeling.

Chemical modifications to the histones, like adding acetyl groups, acetylation, tend to loosen the chromatin and activate genes.

Adding methyl groups, methylation, often correlates with tighter packing and gene silencing.

It's another layer of gene regulation.

Okay, so chromatin is the packaged DNA.

And during cell division, this chromatin condenses even further to form visible chromosomes, right?

Exactly.

Humans normally have 46 chromosomes arranged in 23 pairs.

22 pairs of the autosomes, same in males and females.

Right.

And the 23rd pair are the sex chromosomes.

XX for females, XY for males.

How do scientists actually look at these chromosomes?

I've heard of a karyotype.

A karyotype is basically a visual map of a person's chromosomes.

To make one, you take cells, often white blood cells, culture them, and then chemically arrest them during mitosis.

Specifically in metaphase, when the chromosomes are most condensed and visible.

Then you stain them.

You stain them to reveal characteristic banding patterns, take a micrograph, and then digitally cut out and arrange the chromosomes in pairs, ordered by size, from largest chromosome 1 to smallest, plus the sex chromosomes.

And you can see abnormalities this way, like extra or missing chromosomes.

Precisely, or large deletions or translocations.

We use a standard naming system, too.

The short arm of a chromosome is P, the long arm is Q, and regions and bands are numbered.

So a location like XP22 tells you exactly where on the short arm of the X chromosome you're looking.

Interesting.

You mentioned XX for females.

Porth brings up the lion principle.

What's that about?

Yes.

The lion hypothesis, or X inactivation.

Since females have two X chromosomes and males only have one, females randomly switch off one of their X chromosomes in each cell, early in development.

Randomly.

So in some cells, the X from her mother is active, and in other cells, the X from her father is active.

That's exactly it.

Female tissues are essentially a mosaic regarding which X chromosome is active.

It's a dosage compensation mechanism, ensuring females don't have double the dose of X -linked gene products compared to males.

Fascinating.

Okay, let's shift to cell division.

There are two main types,

mycosis and meiosis.

Right.

Mitosis is the standard cell division for growth and repair in our somatic cells, basically.

All cells except sperm and egg precursors.

And the result is two daughter cells that are genetically identical to the parent cell, both with 46 chromosomes.

Correct.

One round of DNA replication followed by one round of division is for making clones of cells.

Meiosis, on the other hand, is different.

It's only for producing gametes, sperm, and eggs.

Yes.

And the goal is different.

Meiosis involves one round of DNA replication, but two rounds of cell division.

The result is four daughter cells, but each has only half the number of chromosomes.

Just 23 single chromosomes, not pairs.

Why only half?

So that when a sperm with 23 chromosomes fertilizes an egg with 23 chromosomes, the resulting zygote gets back to the normal 46.

Makes sense.

And meiosis is where genetic variation really gets shuffled around, isn't it?

Hugely important point.

The major source of variation is crossing over.

During the first meiotic division, metaphase 1, the paired homologous chromosomes actually exchange segments.

They swap bits of DNA.

So the chromosomes you pass on aren't identical to the ones you inherited.

They're shuffled combinations.

Exactly.

It creates new combinations of alleles on each chromosome.

This genetic recombination is crucial for variation within a population.

And the output is different for males and females too, right?

Yeah.

In males, meiosis results in four functional sperm cells.

In females, the divisions are unequal, producing one large, mature ovum egg and three tiny polar bodies that typically degenerate.

All right.

Now let's talk about how these genes and traits are actually passed down through generations.

We need some terminology first.

Genotype versus phenotype.

Right.

Your genotype is your actual genetic makeup.

The specific alleles you carry for a particular gene or set of genes, it's the stored information.

And phenotype.

That's the observable trait what we actually see or measure.

It could be physical like eye color or biochemical, like having a certain enzyme level.

Phenotype results from the genotype interacting with the environment.

Okay.

And you mentioned alleles.

A gene sits at a specific place on a chromosome.

It's locus.

Alleles are just the different versions of that gene found at that locus.

Perfect.

The gene for eye color has alleles for blue, brown, green, et cetera.

So let's start simple with Mendelian inheritance traits determined by a single gene.

This is based on Gregor Mendel's work, of course.

It deals with dominant and recessive alleles.

A dominant allele exerts its effect even if you only have one copy.

So if A is dominant and A is recessive, both genotypes AA and AA will show the dominant phenotype.

And a recessive allele only shows its phenotype if you have two copies of it, the A genotype.

Precisely.

Porth uses the example of eye color, though it's a bit more complex in reality.

But using the simple model, if brown B is dominant to blue B, someone with BB or B has brown eyes.

Only someone with B has blue eyes.

And we can predict the chances of inheritance using a Punnett square.

Yeah.

It's a simple visual tool.

If you have two heterozygous parents, both B, so they have brown eyes but carry the blue allele, the Punnett square shows the possible combinations in their offspring.

Let's see.

You'd get BB, BB, BB, BB, so that's a one in four chance or 25 % of having a child with blue eyes.

Exactly.

And a 75 % chance of brown eyes, BB or B.

The heterozygous individuals, B, are called carriers of the recessive allele.

They don't show the recessive trait themselves, but they can pass the allele on.

Okay, that covers single gene traits.

But most human traits, and especially diseases, aren't that simple, are they?

No, definitely not.

Most traits are much more complex.

Polygenic inheritance is very common.

This means multiple genes, often at different loci on different chromosomes, contribute to a single trait.

Each gene might have a small additive effect.

Height is a classic example.

And then there's multifactorial inheritance.

What does that add?

That adds the environment.

Multifactorial traits result from the combined influence of multiple genes plus environmental factors, things like heart disease, diabetes, even some cancers.

They have genetic predispositions, but lifestyle and environment play huge roles, too.

So genes load the gun, environment pulls the trigger kind of thing.

That's a common analogy.

One more layer of complexity Porth mentions is genetic imprinting.

This one's really interesting.

What happens there?

Normally, it doesn't matter whether you inherit an allele from your mother or your father.

But with imprinted genes, the expression of the gene depends on its parental origin.

One copy, either the maternal or paternal, is silenced, often by methylation.

So only the copy from the other parent is active.

Whoa.

So the parental genomes don't contribute equally for those specific genes.

Exactly.

It violates the standard Mendelian assumption that both alleles are potentially active.

It's involved in some specific syndromes and developmental processes.

This brings us to how we use all this knowledge.

The technology has exploded, right?

Starting with the Human Genome Project.

Absolutely.

Completed back in 2003, it gave us the first near -complete sequence of human DNA.

Some surprises came out of it.

Like finding fewer genes than expected?

Yeah, only around maybe 20 ,000 to 25 ,000 protein coding genes, not the 100 ,000 previously estimated.

And maybe the biggest finding was just how similar we all are genetically.

99 .9 % identical DNA sequence between any two unrelated people.

It's that tiny 0 .1 % difference that accounts for all our individual variation.

Precisely.

And understanding that variation is key to personalized medicine.

This led to projects like the haplotype map or HapMap.

Okay, what's that focused on?

It focuses on common patterns of human genetic variation.

Specifically, single nucleotide polymorphisms, or SNPs, pronounced SNPs.

SNPs are just single base pair differences in the DNA sequence between individuals.

That's right.

They're the most common type of genetic variation.

Now, SNPs that are located physically close together on a chromosome tend to be inherited together as a block.

Such a block of linked SNPs is called a haplotype.

So instead of tracking millions of individual SNPs, you can track these haplotype blocks.

Exactly.

The HapMap project identified common haplotypes in different populations and found specific tag SNPs that can represent these blocks.

This makes genome scanning much more efficient.

And the clinical relevance is?

Huge.

By comparing the haplotypes or specific SNPs of people with a disease versus those without, we can find genetic variations associated with disease risk.

Even more immediately, this applies to pharmacogenetics.

Predicting drug response based on genes.

Yes.

Your specific SNPs and haplotypes can predict how you'll metabolize a drug, how effective it will be, or if you're likely to have side effects.

This is already being used to guide dosing for some medications, like warfarin.

It's tailoring treatment to your individual genotype.

Amazing.

What about actually manipulating DNA, recombinant DNA technology?

This is where we combine DNA sequences that wouldn't normally occur together in nature.

It relies on a couple of key molecular tools.

Like molecular scissors and glue?

Pretty much.

Restriction enzymes are the scissors they recognize and cut DNA only at specific short sequences.

And DNA ligus is the glue it joins DNA fragments back together.

How is this used?

Well, you can cut out a human gene, say for insulin, and use ligus to paste it into a bacterial plasmid, a small circular piece of DNA.

Then you put that recombinant plasmid back into bacteria.

And the bacteria become little factories, churning out human insulin.

Exactly.

That's how we make therapeutic human insulin, growth hormone, clotting factor 8 for hemophilia, ritopoietin to treat anemia, lots of critical protein drugs.

We also use related techniques for diagnostics, like DNA fingerprinting.

Right.

That uses restriction enzymes to cut DNA into fragments.

Since everyone's DNA sequence is slightly different, those SMPs, the enzymes will cut at different places, creating fragments of different lengths.

You separate these fragments by size, creating a unique banding pattern.

Like a genetic barcode.

Used in forensics.

Precisely.

The pattern is highly individual.

Porth mentions the odds of a random match can be incredibly low, like 1 in 100 ,000 to 1 in a million, making it powerful for identification.

Looking ahead, what about therapies that directly target genes?

Gene therapy.

That's the goal correcting or compensating for faulty genes.

Often involves using a modified virus, like an adenovirus, as a vector to deliver a working copy of the gene into the patient's cells.

It's had some successes, but also faces challenges, like delivery and immune responses.

Is there anything newer on the horizon?

Yes.

A really exciting strategy is RNA interference, or RNAi.

Instead of adding a gene, this aims to silence a specific, unwanted gene.

How does that work?

You introduce small, double -stranded RNA molecules that match the sequence of the target mRNA.

This triggers a cellular mechanism that finds and destroys that specific mRNA.

So you stop the bad protein from ever being made.

Exactly.

You interfere with the messenger RNA.

It's incredibly specific.

It's a powerful research tool.

We call it reverse genomics, because you can silence a gene and see what happens.

And it has huge therapeutic potential, maybe for treating viral infections or genetic disorders by shutting down the problematic gene expression.

Wow.

Okay.

So we've gone from the basic DNA helix all the way to these really sophisticated technologies like RNAi.

We've seen how DNA is transcribed to RNA, translated to protein, how it's all packaged.

How traits are inherited through Mendelian and more complex patterns.

And how mapping that tiny 0 .1 % variation with tools like HapMap is paving the way for truly personalized medicine.

And throughout, the theme is regulation.

From transcription factors, to chromatin remodeling, to chaperones folding proteins, it's all tightly controlled.

Which leads to, maybe, a final thought for our listener.

Go for it.

We've talked about these amazing technologies like gene therapy or RNAi.

We can identify the faulty gene.

We can design the therapeutic molecule.

But the huge challenge, the real frontier right now in applying this, is delivery, isn't it?

Exactly.

If you need to correct a gene or silence an mRNA in, say, liver cells or neurons throughout the brain, trillions of cells, how do you get that therapeutic molecule safely and effectively to all those specific cells and only those cells without triggering a massive immune reaction or having it degraded instantly?

That interface between the genetic knowledge and the practicalities of getting it into the body,

that's where so much work is happening now.

It absolutely is.

That's the cutting edge where genetics meets applied pathophysiology.

A fascinating place to leave it.

Well, thank you for walking us to that intricate world of genetic control.

My pleasure.

It's fundamental stuff.

And thank you all for joining us on this deep dive.

From the whole team, we appreciate you listening and we'll see you next time.